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Bleeding from a peptic ulcer is a common medical emergency, and 
although most upper gastrointestinal bleeding stops spontaneously, 
15 - 20% continues or recurs.1 Stratification systems, such as the 
Rockall score and Forrest classification, which are based on clinical 
and endoscopic factors, respectively, define those at high risk.2,3 Their 
use identifies patients who have a substantially increased risk of 
morbidity and mortality.4 After appropriate resuscitation, endoscopic 
therapy is the primary and most effective therapeutic modality 
for controlling a bleeding peptic ulcer.1 Current opinion favours 
the use of combined endoscopic therapy, i.e. adrenalin injection 
combined with thermocoagulation (gold probe) or a mechanical clip 
device.5,6 There are no local data detailing the efficacy of endoscopic 
therapy, which at our institution until 2 years ago relied on the single 
therapeutic modality of adrenalin injection. We aimed to determine 
the success in controlling bleeding and the overall and surgical 
mortality rates in patients undergoing endoscopic intervention for 
bleeding peptic ulcers. This in turn would establish a benchmark for 
current and future comparison as combined haemostatic modalities 
are introduced into our endoscopic practice.
Methods
This retrospective review of endoscopic and folder data from 1 
January 2004 to 31 December 2009 at a single tertiary hospital 
included 227 patients undergoing emergency endoscopic therapy for 
non-variceal peptic ulcer bleeding. Only patients with documented 
Forrest classification 1a (active spurting of blood), 1b (oozing 
blood), 2a (a non-bleeding visible vessel) and 2b (adherent blood 
clot) gastric and duodenal ulceration and who received adrenalin 
injection therapy were considered eligible and included.3 The rates 
of surgical intervention and day 3 (D3) and day 30 (D30) post-
admission mortality were considered primary endpoints. The Rockall 
score, a validated admission and post-endoscopy risk assessment 
scoring system that incorporates age, presence of shock, co-morbidity 
and the endoscopic stigmata of bleeding, was calculated for each 
patient.2 Other variables analysed included demographics (age and 
gender), ulcer type, current use of non-steroidal anti-inflammatory 
analgesics (NSAIDs) and/or salicylate use, and the presence of 
Helicobacter pylori infection. The use of intravenous or oral proton 
pump inhibition (PPI) and number of blood units transfused were 
also analysed. 
The rate of rebleeding after primary endoscopic therapy was 
analysed. Rebleeding was considered as a new period of bleeding 
after initial endoscopic haemostasis, based on clinical suspicion as 
defined by recurrent haematemesis and/or haematochezia, fresh 
blood in the nasogastric tube, a drop in haemoglobin or circulatory 
instability (as defined by a blood pressure below 90/60 mmHg and a 
heart rate above 100 beats/min).
Patients with suspected acute peptic ulcer bleeding were admitted 
to hospital and resuscitated, and underwent emergency gastroscopy 
within 24 hours of admission. Endoscopy was performed in a 
dedicated endoscopy suite during working hours and in theatre after 
hours. All patients requiring endoscopic therapy received adrenalin 
1:10 000 solution mixed with normal saline to a 10 ml solution. 
Additional solution was administered to control bleeding, if required. 
No adjuvant endoscopic therapy was used (i.e. thermocoagulation 
or mechanical devices). The endoscopy was completed by senior 
registrars in both surgical and medical gastroenterology training 
programmes. A biopsy sample to determine the presence of H. pylori 
infection by either rapid urease testing (National Health Laboratory 
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Background. Endotherapy is the primary modality for the control of 
bleeding from peptic ulceration.
Objective. To assess the efficacy of endoscopic intervention for 
high-risk bleeding peptic ulcer disease and to benchmark our 
surgical and mortality rates.  
Methods. Two hundred and twenty-seven patients with peptic 
ulcers stratified by Rockall and Forrest scores as being at high 
risk for rebleeding underwent therapeutic intervention (adrenalin 
injection) between January 2004 and December 2009. The median 
age of the patients was 57 years (range 19 - 87 years); 60% were 
males.
Results. Primary endoscopic haemostasis failed in 51/227 
patients (22.5%); 18 patients (7.9%) required surgery for bleeding 
not controlled at initial or second endoscopy; and 29 patients 
(12.8%) died, 12 by day 3 and 17 by day 30. Fifteen patients, all 
with significant medical co-morbidity, died after successful primary 
endotherapy, and 4 died after surgery. Surgical patients required 
more blood (odds ratio (OR) 1.45, p=0.0001) than those not 
undergoing surgery, but had similar mortality. Rebleeding was the 
only predictor of death in patients who died by day 3 (OR 18.77). 
A high Rockall score was the only predictor of death by day 30 (OR 
1.98).
Conclusion. The overall surgical and mortality rates were 7.9% 
and 12.8%, respectively. Over half the deaths resulted from medical 
co-morbidity, despite successful primary endotherapy. This finding 
is supported by the use of the Rockall score as a predictor of 
mortality at day 30. Improving the technical success of primary 
endoscopic haemostasis, currently 77.5%, has the potential to 
reduce rebleeding after primary endotherapy, a predictor of death 
at day 3 in this study.
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Service, Cape Town) or formal histological evaluation was taken at 
the discretion of the endoscopist. 
Patients in whom primary endoscopic control of bleeding failed 
were assessed for surgical intervention. The surgical procedure 
undertaken was transfixion of the offending vessel and appropriate 
closure of the access enterotomy. Patients in whom primary 
endoscopic therapy was successful but who had an episode of 
rebleeding underwent a second endoscopy and attempt at endoscopic 
control. Failure to control bleeding at second endoscopy resulted in 
re-assessment for surgical intervention.
Data pertaining to the gastroscopy were captured on a standard 
pro-forma used at the institution and completed for all patients 
undergoing endoscopy. Site and description of the ulcer, the presence 
or absence of stigmata of bleeding, Forrest classification, use of 
adrenalin, and whether or not H. pylori was investigated for were 
recorded. The first author personally reviewed these data for accuracy 
and entered the information onto a data sheet. 
All patients received post-endoscopy PPI. A patient was considered 
to have been given the medication if the drug prescription chart was 
signed by the administering nursing sister. 
Statistical analysis was performed using Stata software (Stata 
Statistical Software: Release 11, College Station, TX: StataCorp LP). 
Continuous variables were expressed as medians and interquartile 
ranges (all variables in the final analysis had a non-Gaussian 
distribution). For the purpose of analysis, the Forrest classification 
variable was dichotomised as 1a/1b versus 2a/2b.  The Mann-Whitney 
test was used to assess continuous variables, while the chi-square or 
Fisher’s exact test was used for categorical variables. Univariate 
analysis was performed initially for each variable. Variables differing 
between groups with a significance level of p<0.2, as well as other 
possible confounders identified a priori, were then entered into a 
series of multivariate logistic regression models. Age was treated as 
a continuous variable. Models were built sequentially, starting with 
the variable most strongly associated with the outcome. A p-value of 
≤0.05 was considered significant.
The study was approved by the University of Cape Town Ethical 
Review Board.
Results
Of the 227 patients reviewed, 60.4% were males and 39.6% females, 
with a median age of 57 years (range 19 - 87 years). Duodenal 
ulceration was found in 94 patients, gastric ulceration in 123 and 
both types in 10. H. pylori was tested for in 121 patients, of whom 
63 (52.1%) were positive. One hundred and forty-eight patients 
(65.1%) were taking either NSAIDs (N=87), salicylates (N=61) or 
both. Overall 111 patients received intravenous PPI, as a continuous 
infusion (bolus of 80 mg and then 8 mg/h) in 85 patients and as bolus 
doses (40 mg daily) in 26; 105 patients received oral PPI at a variable 
dose of 20 or 40 mg twice daily. In 11 patients the use of PPI could 
not be confirmed.
In 176 subjects (77.5%) primary endoscopic haemostasis was 
achieved. Of the 51 patients (22.5%) in whom primary endoscopic 
haemostasis failed, 38 (16.7%) underwent a second endoscopic 
attempt, which was unsuccessful in 14 (36.8%); 24 (63.2%) patients 
had successful second endoscopic therapy (Fig. 1).
Patients undergoing surgery
Eighteen patients (7.9%) required surgical intervention for bleeding 
not controlled at initial (n=8) or second endoscopy (n=10). There 
was no difference in demographic data when comparing the surgical 
and non-surgical groups (Table 1). There was also no significant 
difference when comparing the Rockall score, ulcer type, current 
use of NSAIDs and/or salicylates, use of PPI, presence of H. pylori 
infection or mortality between the groups.
However, on univariate analysis subjects requiring surgery 
demonstrated more severe degrees of bleeding on Forrest 
classification (p=0.01). This association persisted on multivariate 
modelling, but was not statistically significant (odds ratio (OR) 0.26, 
95% confidence interval (CI) 0.07 - 1.02 for 2a/2b v. 1a/1b) (Table 2). 
Subjects requiring surgery also had significantly higher transfusion 
requirements (p<0.0001), which remained significant on regression 
analysis (OR 1.45, 95% CI 1.24 - 1.69).
Mortality data
Overall, 29 patients (12.8%) died, 12 (5.3%) by D3 and 17 (7.5%) by 
D30. There was no difference in demographic data when comparing 
overall mortality (29 patients) and the rest of the group (198 patients), 
whether by D3 or D30. On logistic regression analysis, after adjusting 
for confounders, rebleeding was the only independent predictor of 
death by D3 (OR 18.77, 95% CI 3.33 - 105.67). A high Rockall score 
was the only predictor of death by D30 (OR 1.98, 95% CI 1.3 - 2.99). 
There was no significant difference between the patients who died 
and those who survived when comparing ulcer type, current use of 
NSAIDs and/or salicylates, use of PPI, or the presence of H. pylori 
infection, either by D3 or D30. 
Of the 8 patients who underwent surgery for failed primary 
haemostasis, only 1 died, by D30. Five patients in whom primary 
endoscopic therapy failed were deemed unfit for or died before 
surgical intervention (4 by D3 and 1 by D30). Of the 10 patients who 
underwent surgical intervention for failed second haemostasis, 3 died 
(2 by D3 and 1 by D30). Four patients in whom a second haemostasis 
failed did not undergo surgery and died (3 by D3 and 1 by D30).
Overall 4 patients (22.2%) died postoperatively, 2 by D3 and 2 by 
D30. All four patients had severe co-morbid medical conditions, and 
these deaths were not considered to be directly related to ongoing 
bleeding. Of the 2 patients who died by D3, one had metastatic 
breast carcinoma and chronic renal failure with a creatinine level 
of 668 mmol/l (39 - 90 mmol/l) and the other postoperative sepsis 
(procalcitonin level 52 µg/l (0.0 - 0.5 ug/l)).
It is important to note that of the 29 patients who died, 15 died after 
successful primary endoscopic therapy, 2 by D3 and 13 by D30. All 
15 had significant co-morbid medical conditions. Of the 2 patients 
who died by D3, one had metastatic pseudosarcomatoid carcinoma 
of thymic origin and the other chronic renal failure (creatinine level 
422 mmol/l (39 - 90 mmol/l)) resulting from diabetes mellitus and 
hypertension. 
Discussion
In these high-risk patients with peptic ulcer bleeding, our rate of 
surgical intervention of 7.9%, using adrenalin injection alone, is 
Fig. 1. Management algorithm (*5 patients unfit for/or died prior to surgical 
intervention, **4 patients unfit for/or died prior to surgical intervention; for 
details refer to the  paragraph on mortality data).
RESEARCH
RESEARCH
292  May 2012, Vol. 102, No. 5  SAMJ
in line with published data of 2.5 - 10.7%.5,7,8 Patients undergoing 
surgery had a higher Forrest score and transfusion requirement 
which, in turn, reflects their higher risk. However, the Rockall score 
was not found to be a significant predictor for surgery. The need for 
surgical intervention also had no impact on mortality.
The overall benchmark mortality rate was 12.8%, which is high 
but comparable to published mortality rates of 4 - 14%.5,7,9,10 Of our 
patients who died, 52% were in the successful primary endoscopic 
therapy group. Medical co-morbidity accounted for these deaths, 
a factor supported in our study by the use of the Rockall score as 
a predictor of death by D30. The Rockall system scores co-morbid 
disease on admission highly, and a score ≥8 (defined as age over 
60, evidence of shock on admission, co-morbid disease and major 
stigmata of bleeding) predicts a rebleeding rate of 48% and mortality 
rate of 39%.2
Our failure rate of 22.5% after primary endoscopic control is of 
concern and is higher than the 7 - 20% found in similar studies.7,9,11 
In addition, our success rate of 63.2% at second endoscopic control 
falls outside the published range of 72 - 75%.12,13
Rebleeding after primary endoscopic intervention was a significant 
predictor of death by D3. Improving on the technical success rate 
of primary endoscopic haemostasis, currently 77.5% in our study, 
has the potential to reduce rebleeding and therefore mortality 
rate. A possible solution would be to use both adrenalin injection 
and thermocoagulation, so-called dual therapy, for haemostasis. 
The addition of thermocoagulation (e.g. gold probe diathermy) 
is considered the current standard of care,5,8 but was not used in 
our unit during the period under review. Recently the volume of 
adrenalin and saline solution injected at endoscopy has been shown 
to be of importance in achieving haemostasis.14 However, our study 
did not control for volume of injection, so its contribution in terms 
of improving outcome could not be analysed.
The high prevalence (65%) of NSAID and salicylate use is not an 
unusual finding in studies of bleeding ulcers, with reported figures in 
excess of 50%.9,10,15 H. pylori infection is an independent risk factor for 
the development of peptic ulceration.15 In addition, a high prevalence 
of H. pylori infection (68%) was demonstrated in a prospective group 
of dyspeptic patients undergoing endoscopy at our institution.16 In our 
study the use of NSAIDs and the presence of H. pylori infection did not 
influence the rate of surgery or mortality. The relatively low prevalence 
of H. pylori infection (52% of those tested) in our study could be due to 
non-testing in 106 patients (47%) and to the presence of blood in the 
stomach, a well-described cause of a false-negative urease test.17 
In conclusion, this retrospective analysis provides us with 
benchmark data using adrenalin injection therapy alone, which we 
will be able to compare with results when additional modalities 
of endoscopic therapy are used. Although the rate of surgical 
intervention is not high, the rebleeding and mortality rates are high 
Table 2. Multivariate model of risk factors associated with surgery 
Factor Crude OR (95% CI) Adjusted OR (95% CI) p-value
Forrest classification 0.3 (0.1 - 0.78) 0.26 (0.07 - 1.02) 0.053
Blood transfusion 1.4 (1.2 - 1.6) 1.45 (1.24 - 1.69) <0.0001
Gender 0.56 (0.19 - 1.63) 0.66 (0.17 - 2.53) 0.54
Age 0.98 (0.96 - 1.01) 0.99 (0.95 - 1.04) 0.71
Rockall  score 1.22 (0.94 - 1.61) 0.99 (0.68 - 1.45) 0.96
OR = odds ratio; CI = confidence interval.
Table 1. Characteristics of surgical and non-surgical groups
Surgery (n=18) No surgery (n=209) p-value
Age (yrs) (median (IQR)) 52 (45 - 69) 58 (45 - 69) 0.25
Gender (male) (n (%)) 13 (72) 124 (59) 0.28
Forrest classification (n (%))
   1a/1b
   2a/2b
13 (72)
5 (28)
123 (59)
86 (41)
0.01
Rockall score (median (IQR)) 6 (5 - 8) 5 (3 - 7) 0.14
Units of blood transfused (median (IQR)) 8 (7 - 14) 3 (0 - 5) <0.0001
PPI use (n (%))
   Intravenous (n)
   Oral (n)
15 (83)
9
6
201 (96)
102
99
0.49
H. pylori present in those tested (n (%)) 7/11 (64) 56/110 (51) 0.42
Ulcer type
   GU (n (%))
   DU (n (%))
   Both (n (%))
8 (44.5)
9 (50)
1 (5.5)
115 (55)
85 (40.6)
9 (4.4)
0.69
Mortality D3 (n (%)) 2 (11) 10 (4.7) 0.25
Mortality D30 (n (%)) 2 (11) 15 (7.2) 0.60
IQR = interquartile range; GU = gastric ulcer; DU = duodenal ulcer; D3 = day 3; D30 = day 30. 
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and we need to attempt to improve these outcomes. The introduction 
of more effective endoscopic therapy will probably result in reduction 
of rebleeding. This improvement, however, will only be effective 
in reducing the proportion of patients who die from rebleeding, 
which in this series was less than 50% of the total deaths. Despite 
the limitations of a single-centre study, our results may be applicable 
to other institutions using single-modality haemostatic therapy. The 
addition of a second modality to adrenalin injection is the focus of a 
prospective randomised trial, currently in progress. 
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